6 min. read

Virta Health study. FDA-cleared algorithms. Arthritis DTx.

In this article:

This is the fifth edition of the E&O weekly newsletter for paying subscribers. Topics discussed include lessons from Theranos, Virta’s two-year study, FDA-cleared algorithms, DTx generics and more.

Issue 005. Virta Health study. FDA-cleared algorithms. Arthritis DTx.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 71 percent open rate. Here's what's happening this week:

Don't click those, read on for more important studies, deals, insights, frameworks, and news below.

Did this get forwarded to you? Not yet a paying subscriber? You can sign up right over here.

Virta's two-year study results

The big outcomes story this week goes

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles